Narinder Singh
Chief Tech/Sci/R&D Officer at ARCELLX, INC.
Narinder Singh active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ARCELLX, INC. | Chief Tech/Sci/R&D Officer | 2021-09-30 | - |
Career history of Narinder Singh
Former positions of Narinder Singh
| Companies | Position | Start | End |
|---|---|---|---|
| FORTE BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2021-07-31 | 2021-09-30 |
| AIMMUNE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2020-07-05 | 2021-06-30 |
| GENOCEA BIOSCIENCES, INC. | Corporate Officer/Principal | 2018-02-28 | 2020-06-30 |
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2015-06-30 | 2018-02-28 |
Training of Narinder Singh
| Indian Institute of Technology New Delhi | Graduate Degree |
| University of Houston | Graduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Statistics
International
| United States | 8 |
| India | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 2 |
| Graduate Degree | 2 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| ARCELLX, INC. | Health Technology |
| FORTE BIOSCIENCES, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
- Stock Market
- Insiders
- Narinder Singh
- Experience
